AMDL, Inc. to Present at 5th Annual Winter Technology Conference Hosted by Security Research Associates, Inc.
March 06 2009 - 9:30AM
PR Newswire (US)
TUSTIN, Calif., March 6 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE
Alternext US: ADL), a US-based pharmaceutical company with major
operations in China, announced today its Executive Chairman and
Chief Executive Officer Mr. Douglas MacLellan will present at
Security Research Associates' (SRA) 5th Annual Winter Technology
Conference on Monday, March 9, 2009. During the 5th Annual Winter
Technology Conference, Mr. MacLellan will provide details of AMDL's
2009 business strategy, expanding product portfolio, and FY2009
financial projections. Mr. MacLellan's presentation will take place
at 12:30 p.m. PDT in the Russian Room in the Omni Hotel located in
San Francisco, CA. Conference attendees will include a select group
of institutional portfolio managers and analysts and feature CEOs
and CFOs from some of the fastest growing companies in the
technology sector. Founded in 1987, AMDL operates three distinct
business divisions that include: (i) In Vitro Diagnostics, (ii)
Cancer Therapeutics, and (iii) China-based pharmaceutical
manufacturing and distribution. Collectively, these business units
focus on the development, manufacturing, distribution and sales of
high quality generic pharmaceuticals, nutritional supplements,
cosmetic and medical diagnostic products in the US, China, Korea,
Taiwan and other markets throughout the world. For the past four
consecutive fiscal years, AMDL has achieved 100% or more growth in
gross revenues and expects to continue this forward momentum in
2009 as it executes an aggressive business strategy focused on
expanding its market presence in China and other select
international markets. Management issued financial guidance for
FY2009 forecasting gross revenues between US$64 to $72 million, and
net income between US$8 and $12 million after taxes and before
foreign currency translation gains or losses. This guidance
represents sales for AMDL's China-based operations only and does
not include product sales for DR-70 or Elleuxe. AMDL believes
anticipated revenues from these two products could potentially
result in an additional US$25 million in additional gross revenues.
In FY2008 AMDL achieved gross revenues between $32 million - $36
million vs. $15 million in FY2007, and net income after foreign
currency translation of between $2.4 and $2.6 million. For FY 2007,
net loss after foreign currency translation was approximately $1.26
million. AMDL is listed on the American Stock Exchange Alternext US
under the symbol "ADL". In 2007, AMDL earned $15 million in gross
revenues and the Company plans to issue 2008 earnings results later
this month. AMDL employs approximately 510 people in the US and
China. Webcasting of all Company presentations during the SRA
conference will be accessible following the event by visiting:
http://www.wsw.com/webcast/sra8/ . About AMDL: Headquartered in
Tustin, CA with operations in China, AMDL, Inc., along with its
subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical
company devoted to the research, development, manufacturing, and
marketing of diagnostic, pharmaceutical, nutritional supplement,
and cosmetic products. The Company employs over 490 people in the
US and China. About Security Research Associates, Inc. Security
Research Associates, Inc. (SRA) was founded in San Francisco in
1980 and, today, offers investment banking and M&A services as
well as institutional brokerage services. A boutique firm by
design, SRA works with a select group of portfolio managers from
around the country and focuses on technology and life science
companies in the micro and small cap arenas. For more information
about SRA see our web site at http://www.sracap.com/ or call us at
415-925-0346. Forward Looking Statements: Safe Harbor Statement
under the Private Securities Litigation Reform Act of 1995: The
statements contained in this document include certain predictions
and projections that may be considered forward-looking statements
under securities law. These statements involve a number of
important risks and uncertainties that could cause actual results
to differ materially including, but not limited to, the performance
of joint venture partners, as well as other economic, competitive
and technological factors involving the Company's operations,
markets, services, products, and prices. With respect to AMDL,
Inc., except for the historical information contained herein, the
matters discussed in this document are forward-looking statements
involving risks and uncertainties that could cause actual results
to differ materially from those in such forward-looking statements.
AMDL Contact: Kristine Szarkowitz Director-Investor Relations
(Tel:) 714.380.8832 DATASOURCE: AMDL, Inc. CONTACT: Kristine
Szarkowitz, Director-Investor Relations of AMDL, Inc.,
+1-714-380-8832,
Copyright